Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

Samsung Medical Center300 enrolled

Overview

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Polymorphism CYP19 Aromatase Inhibitor

Eligibility

Sex: FEMALEMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * hormone receptor positiveBreast cancer patient * postmenopausal women * first user of aromatase inhibitor Exclusion Criteria: * premenopausal * The patient who take the other antihormonal therapy * osteoporosis patients

Locations (1)

Samsung Medical Center

Seoul, Seoul, South Korea

Outcomes

Primary Outcomes

The prevalence of CYP19 polymorphism

Time frame: 12. 31. 2011

Secondary Outcomes

The effect of CYP19 polymorphism to the prognosis of AI user

Time frame: 12. 31. 2016

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.